Skip to main content
Erschienen in: Cardiovascular Diabetology 1/2021

Open Access 01.12.2021 | Commentary

Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes

verfasst von: Lucia La Sala, Antonio E. Pontiroli

Erschienen in: Cardiovascular Diabetology | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

In a cohort study performed using primary care databases in a General Practitioners Network, Groenewegen et al. report a clear association between diabetes and incidence of the major chronic progressive heart diseases, notably heart failure (Groenewegen et al. in Cardiovasc Diabetol 20:123, 2021). However, no mention is made of body mass index and hypertension in the methods or in the results. Obesity is linked to hypertension and hypertension is a major risk factor for all cardiovascular diseases, and prospective studies have shown that obesity and hypertension contribute significantly to atrial fibrillation in persons with diabetes. The data would be improved by assessing the role of obesity and of hypertension in the incidence of heart diseases in these patients. This would also lead to a better and personalized treatment of patients with diabetes, for instance through weight loss and intensification of treatment of hypertension, to modify the incidence of atrial fibrillation, ischaemic heart disease and heart failure.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Sir,
In a recent paper Groenewegen et al. report on the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes [1] in the Netherlands. In a longitudinal cohort study performed using primary care databases in a General Practitioners Network, the authors show a clear association between diabetes and incidence of the major chronic progressive heart diseases, notably heart failure, with a more than twice increased risk. However, in this study no mention is made of body mass index in the “Methods” section or in the “Results” section.
Even though the primary interest was to describe the incidence of cardiovascular diseases in diabetes in the real world, the data would gain scientific value by dissecting the role of obesity itself in the incidence of cardiovascular diseases, possibly mediated by hypertension. In fact, obesity is associated with hypertension [2], and hypertension is a major risk factor for all cardiovascular diseases, including coronary heart disease, stroke, atrial fibrillation, heart failure, aortic and peripheral arterial disease, and valvular heart disease [3]. In the prospective cross‑sectional observational NOMED‑AF (Non‑ invasive Monitoring for Early Detection of Atrial Fibrillation) study performed in Poland, atrial fibrillation was observed in 25 % persons with diabetes as compared with 17% persons without diabetes [4]; also, persons with diabetes and atrial fibrillation had more frequently hypertension, obesity, and ischemic heart disease than persons without diabetes. There is no doubt that blood glucose levels represent a direct risk factor for cardiovascular diseases, of increasing value from prediabetes to diabetes, to insulin-treated diabetes [5, 6]. However, the cardiovascular risk gradually increases with increases in blood pressure regardless of the presence of and of the degree of glucose abnormality [7]. Finally, one should consider education and healthy habits of persons with diabetes; in Sweden, less educated people had a poor prognosis and a higher prevalence of CVD risk factors (including poor glycemic control, smoking and obesity) than well educated people [8]. Therefore, it seems wise to assume that diabetes is not a lonely actor responsible for atrial fibrillation, ischaemic heart disease and heart failure. The data of Groenewegen et al. [1] would be improved by assessing, likely through multivariable analysis, the role of obesity and of hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in their patients. This would also lead to a better and personalized treatment of patients with diabetes, for instance through weight loss and intensification of treatment of hypertension, to modify the incidence of atrial fibrillation, ischaemic heart disease and heart failure [2].

Acknowledgements

Not applicable.

Declarations

Not applicable.
Not applicable.

Competing interests

AEP and LSL have no conflict of interest with the contents of this paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Groenewegen A, Zwartkruis VW, Cekic B, de Boer RA, Rienstra M, Hoes AW, Rutten FH, Hollander M. Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovasc Diabetol. 2021;20(1):123.CrossRef Groenewegen A, Zwartkruis VW, Cekic B, de Boer RA, Rienstra M, Hoes AW, Rutten FH, Hollander M. Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes. Cardiovasc Diabetol. 2021;20(1):123.CrossRef
2.
Zurück zum Zitat La Sala L, Tagliabue E, Vieira E, Pontiroli AE, Folli F. High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovasc Diabetol. 2021;20(1):118.CrossRef La Sala L, Tagliabue E, Vieira E, Pontiroli AE, Folli F. High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovasc Diabetol. 2021;20(1):118.CrossRef
3.
Zurück zum Zitat Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–92.CrossRef Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75:285–92.CrossRef
4.
Zurück zum Zitat Gumprecht J, Lip GYH, Sokal A, Średniawa B, Mitręga K, Stokwiszewski J, Wierucki Ł, Rajca A, Rutkowski M, Zdrojewski T, Grodzicki T, Kaźmierczak J, Opolski G, Kalarus Z. Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. Cardiovasc Diabetol. 2021;20(1):128.CrossRef Gumprecht J, Lip GYH, Sokal A, Średniawa B, Mitręga K, Stokwiszewski J, Wierucki Ł, Rajca A, Rutkowski M, Zdrojewski T, Grodzicki T, Kaźmierczak J, Opolski G, Kalarus Z. Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. Cardiovasc Diabetol. 2021;20(1):128.CrossRef
5.
Zurück zum Zitat Sinha A, Ning H, Ahmad FS, Bancks MP, Carnethon MR, O’Brien MJ, Allen NB, Wilkins JT, Lloyd-Jones DM, Khan SS. Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project. Cardiovasc Diabetol. 2021;20(1):66.CrossRef Sinha A, Ning H, Ahmad FS, Bancks MP, Carnethon MR, O’Brien MJ, Allen NB, Wilkins JT, Lloyd-Jones DM, Khan SS. Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project. Cardiovasc Diabetol. 2021;20(1):66.CrossRef
6.
Zurück zum Zitat Schwartz GG, Nicholls SJ, Toth PP, Sweeney M, Halliday C, Johansson JO, Wong NCW, Kulikowski E, Kalantar-Zadeh K, Ginsberg HN, Ray KK. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovasc Diabetol. 2021;20(1):125.CrossRef Schwartz GG, Nicholls SJ, Toth PP, Sweeney M, Halliday C, Johansson JO, Wong NCW, Kulikowski E, Kalantar-Zadeh K, Ginsberg HN, Ray KK. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. Cardiovasc Diabetol. 2021;20(1):125.CrossRef
7.
Zurück zum Zitat Yamada MH, Fujihara K, Kodama S, Sato T, Osawa T, Yaguchi Y, Yamamoto M, Kitazawa M, Matsubayashi Y, Yamada T, Seida H, Ogawa W, Sone H. Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status. Diabetes Care. 2021;25:dc202252.CrossRef Yamada MH, Fujihara K, Kodama S, Sato T, Osawa T, Yaguchi Y, Yamamoto M, Kitazawa M, Matsubayashi Y, Yamada T, Seida H, Ogawa W, Sone H. Associations of Systolic Blood Pressure and Diastolic Blood Pressure With the Incidence of Coronary Artery Disease or Cerebrovascular Disease According to Glucose Status. Diabetes Care. 2021;25:dc202252.CrossRef
8.
Zurück zum Zitat Carlsson S, Andersson T, Talbäck M, Feychting M. Mortality rates and cardiovascular disease burden in type 2 diabetes by occupation, results from all Swedish employees in 2002–2015. Cardiovasc Diabetol. 2021;20(1):129.CrossRef Carlsson S, Andersson T, Talbäck M, Feychting M. Mortality rates and cardiovascular disease burden in type 2 diabetes by occupation, results from all Swedish employees in 2002–2015. Cardiovasc Diabetol. 2021;20(1):129.CrossRef
Metadaten
Titel
Role of obesity and hypertension in the incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes
verfasst von
Lucia La Sala
Antonio E. Pontiroli
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
Cardiovascular Diabetology / Ausgabe 1/2021
Elektronische ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-021-01331-5

Weitere Artikel der Ausgabe 1/2021

Cardiovascular Diabetology 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.